Showing 1,508 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

PrEP science

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

Editor's pick
BusinessWire
7 December 2021
The search for a cure

How Long To An HIV Cure? As GSK Therapy Heads For Human Trials, Where We Are In Fight Against Virus

Editor's pick
News18
1 December 2021
Coronavirus

The New COVID Drugs Are a Bigger Deal Than People Realise

Editor's pick
The Atlantic
29 November 2021
Coronavirus

New licenses could spark manufacture of COVID-19 pills in Africa

Editor's pick
Spotlight
29 November 2021
New & experimental HIV treatments

Gilead and Merck Announce Temporary Pause in Enrolment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir ​​​​​​​

Editor's pick
Gilead Sciences
26 November 2021
Health services & systems

President of Rwanda Urges African Parliaments to Back new African Medicines Agency, the continent's new regulatory authority

Editor's pick
AllAfrica
25 November 2021
Self-testing & home testing

Chembio Diagnostic Systems Prevails in International Arbitration Against BioSure (UK) Ltd

Editor's pick
GlobeNewswire
24 November 2021
New & experimental HIV treatments

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

Editor's pick
FierceBiotech
22 November 2021
Activism & civil society

A Financial Disaster Hits US HIV Agencies in January. Why Won’t Anyone Stop It?

Editor's pick
My Fabulous Disease
16 November 2021
Access to healthcare

African Medicines Agency Treaty Takes Effect – New AMA Agency Should Ease Access to Newer and Safer Medicines

Editor's pick
Health Policy Watch
8 November 2021
New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
Pharmaceutical industry

Thailand’s switch to dolutegravir: more generic versions needed!

Editor's pick
Medicines Patent Pool
31 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
Access to healthcare

New study confirms MPP licences save money and lives

Editor's pick
Medicines Patent Pool
26 October 2021
PrEP policies & guidelines

Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union

Editor's pick
Gilead press release
22 October 2021
Access to healthcare

2021 HIV Market Report: The state of the HIV market in low- and middle-income countries

Editor's pick
Clinton Health Access Initiative
12 October 2021
HIV treatment for children & young people

ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV

Editor's pick
ViiV Healthcare press release
5 October 2021
PrEP science

Most switches to Descovy PrEP are probably unnecessary and some may be harmful

News
1 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
Injectable & long-acting PrEP

FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

Editor's pick
ViiV Healthcare press release
28 September 2021
Pharmaceutical industry

Gilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds

Editor's pick
FiercePharma
27 September 2021
HIV treatment for children & young people

Unitaid, the Clinton Health Access Initiative, and Laurus Labs announce agreement to accelerate development of best-in-class second- and third-line HIV medication for children

Editor's pick
Clinton Health Access Initiative
13 September 2021
Access to healthcare

HIV treatment dolutegravir arrives in more upper-middle-income countries

Editor's pick
Medicines Patent Pool
3 September 2021